Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$17.3 million.

  • Gossamer Bio's Net Cash Flow rose 7046.29% to -$17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.5 million, marking a year-over-year increase of 6404.59%. This contributed to the annual value of $14.1 million for FY2024, which is 11758.95% up from last year.
  • According to the latest figures from Q3 2025, Gossamer Bio's Net Cash Flow is -$17.3 million, which was up 7046.29% from -$2.8 million recorded in Q2 2025.
  • Over the past 5 years, Gossamer Bio's Net Cash Flow peaked at $59.6 million during Q3 2022, and registered a low of -$58.5 million during Q3 2024.
  • Moreover, its 4-year median value for Net Cash Flow was -$17.3 million (2025), whereas its average is -$11.6 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 27017.61% in 2024, then tumbled by 35173.12% in 2025.
  • Quarter analysis of 4 years shows Gossamer Bio's Net Cash Flow stood at -$42.1 million in 2022, then dropped by 20.3% to -$50.7 million in 2023, then skyrocketed by 134.99% to $17.7 million in 2024, then tumbled by 197.44% to -$17.3 million in 2025.
  • Its Net Cash Flow stands at -$17.3 million for Q3 2025, versus -$2.8 million for Q2 2025 and -$17.2 million for Q1 2025.